Search

EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)

On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

Read more

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeting

Professor San Miguel is a member of the Advisory board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Highlights of Past EHA (HOPE) Cairo 2018

EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.

Read more

Highlights of Past EHA (HOPE) Asia 2019

The 1st edition of the Highlights of Past EHA (HOPE) Asia 2019 took place in Kolkata, India. The meeting was organized in partnership with regional and national societies in Asia.

Read more